Research and Markets: Review the Major Developments of the Generics Company Mylan.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37634) has announced the addition of the Espicom Business Intelligence Ltd report: Mylan Generics Company Intelligence Report to their offering.

Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the companys active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Topics Covered

INTRODUCTION

--Mylan Pharmaceuticals

--Mylan Technologies

--UDL Laboratories

--Bertek Pharmaceuticals

PRODUCTS

--Mylan ANDA Approvals, 2002-05

--Recent product approvals

--Cyclobenzaprine

--Alprazolam

--Rabeprazole (tentative)

--Zonisamide

--Bisoprolol

--Glimepiride

--Amlodipine

--Metformin ER

--Ondansetron (tentative)

--Terbinafine

--Anagrelide capsules

--Quinapril and hydrochlorothiazide 

--Olanzapine tablets (tentative)

--Modafinil tablets (tentative)

--Citalopram

--Fentanyl

--Quinapril

--Oxybutynin (tentative)

FINANCIAL RESULTS

--Latest Full Year Highlights

--Latest Full Year Results

--Segment Data

--Generic Segment

--Full Year Results, 2001-05

--Branded Segment

--Full Year Results, 2001-05

--Latest Quarterly Results, Q3 2006 (quarter ended December 2005)

MYLAN LABORATORIES GENERIC COMPANIES ANALYSIS

--ii Quarter I, 2006

--Quarterly Results (US$000s)

MAJOR DEVELOPMENTS

--Mergers, acquisitions and agreements

--Tamiflu production

--King Pharmaceuticals merger called off

--Litigation

--Modafinil

--Mylan enters oxybutynin supply agreement with Ortho-McNeil and ALZA

--Missouri AG alleges firms involved in AWP inflation scheme

--Court denies Pfizers summary judgement motion in amlodipine litigation

--Mylan wins oxybutynin patent litigation

--ALZA to appeal

--Ortho-McNeil gains levofloxacin ruling against Mylan

--'Authorised Generics'

--Fentanyl

--Paclitaxel

--Average wholesale price

--Mylan dismissed from AWP litigation

Summary

Headquartered in Pennsylvania, Mylan's roots date back to January 1961, when Mylan Pharmaceuticals was formed; Mylan Laboratories was incorporated in Pennsylvania in August 1970. The company produces both generic and branded pharmaceuticals for the US market; generics through Mylan Pharmaceuticals, Mylan Technologies and UDL Laboratories, and branded products through its Mylan Bertek Pharmaceuticals unit. The company's generics portfolio covers a variety of dosage forms, including immediate and extended-release oral tablets and capsules, and transdermal patches. Additionally, it repackages and markets multi-source and single-source products in unit dose form for the institutional marketplace.

Mylan employs around 2,800 people across its units.

--Mylan Pharmaceuticals

--Mylan Technologies

--UDL Laboratories

--Bertek Pharmaceuticals

In June 2005, Mylan reported that it will be closing its Bertek subsidiary, and will transfer responsibility for selling Mylan Berteks products to its Mylan Pharmaceuticals and UDL subsidiaries. Mylan stated that the existing Mylan Bertek business is not the type of brand platform that would enable Mylan to fulfil its objective of becoming a more balanced specialty pharmaceutical company. It believes that closing Mylan Bertek will streamline its operations and result in significant cost savings.

For more information visit http://www.researchandmarkets.com/reports/c37634